ARTICLE | Company News
Myriad Genetics, Teva deal
April 9, 2012 7:00 AM UTC
Myriad will use its BRACAnalysis test to detect mutations in breast cancer 1 early onset (BRCA1) and BRCA2 genes in patients to be enrolled in a Phase I/II trial of an undisclosed compound from Tev...